Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | CTSS | P25774 | 3/20 | 0.52 |
| ▸ | CTSL | P07711 | 2/20 | 0.52 |
| ▸ | SYK | P43405 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | CTSK | P43235 | 3/20 | 0.48 |
| ▸ | KYNU | Q16719 | 1/20 | 0.48 |
| ▸ | CTSB | P07858 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13618128 | 1.00 | LMNA (0.55) | LMNASMN1; SMN2HTTCTSSCTSL | |
| SCHEMBL2525365 | 1.00 | LMNA (0.55) | LMNASMN1; SMN2HTTCTSSCTSL | |
| SCHEMBL14617628 | 0.88 | LMNA (0.55) | LMNASMN1; SMN2HTTCTSSCTSL | |
| SCHEMBL2142734 | 0.88 | LMNA (0.58) | LMNASMN1; SMN2HTTCTSSCTSL | |
| SCHEMBL3701587 | 0.88 | LMNA (0.58) | LMNASMN1; SMN2HTTCTSSCTSL | |
| SCHEMBL2646824 | 0.88 | LMNA (0.58) | LMNASMN1; SMN2HTTCTSSCTSL | |
| SCHEMBL16533444 | 0.85 | LMNA (0.60) | LMNASMN1; SMN2HTTL3MBTL1MAPT | |
| SCHEMBL8274264 | 0.85 | LMNA (0.56) | LMNASMN1; SMN2HTTCTSSCTSL | |
| SCHEMBL8132360 | 0.85 | CTSS (0.53) | LMNASMN1; SMN2HTTCTSSCTSL | |
| SCHEMBL8274278 | 0.85 | LMNA (0.56) | LMNASMN1; SMN2HTTCTSSCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9315498-B2 | Arlethynyl derivatives | HOFFMAN-LA ROCHE INC. (US) | 2016-04-19 | — | — | US | disclosed |
| EP-2558457-B1 | ARYLETHYNYL DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2016-03-09 | — | — | EP | disclosed |
| US-20140155602-A1 | Arlethynyl Derivatives | HOFFMANN-LA ROCHE INC. (US) | 2014-06-05 | — | — | US | disclosed |
| US-8735599-B2 | Substituted imidazole derivates | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2014-05-27 | — | — | US | disclosed |
| US-8618296-B2 | Arylethynyl derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-12-31 | — | — | US | disclosed |
| US-20130274464-A1 | Arylethynyl Derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2013-10-17 | — | — | US | disclosed |
| US-8513273-B2 | Arylethynyl derivatives | HOFFMANN-LAROCHE INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-20130178456-A1 | ARYLETHYNYL DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2013-07-11 | — | — | US | disclosed |
| US-8420661-B2 | Arylethynyl derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-04-16 | — | — | US | disclosed |
| EP-1765789-B1 | N-(1-(1-BENZYL-4-PHENYL-1H-IMIDAZOL-2-YL)-2,2-DIMETHYLPROPYL)BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS KINESIN SPINDLE PROTEIN (KSP) INHIBITORS FOR THE TREATMENT OF CANCER | NOVARTIS AG (CH) | 2013-02-27 | — | — | EP | disclosed |
| EP-2558457-A1 | ARYLETHYNYL DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2013-02-20 | — | — | EP | disclosed |
| US-20130017196-A1 | SUBSTITUTED IMIDAZOLE DERIVATIVES | CHIRON CORPORATION | 2013-01-17 | — | — | US | disclosed |
| US-8318791-B2 | Substituted imidazole derivatives | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2012-11-27 | — | — | US | disclosed |
| WO-2011128279-A1 | ARYLETHYNYL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-10-20 | — | — | WO | disclosed |
| US-20110251169-A1 | Arylethynyl derivatives | HOFFMANN-LA ROCHE, INC. | 2011-10-13 | — | — | US | disclosed |
| US-20090258016-A1 | Substituted imidazole derivatives | WANG WEIBO | 2009-10-15 | — | — | US | disclosed |
| US-20090227680-A1 | Amino Acid Derivatives | PFIZER, INC. (US) | 2009-09-10 | — | — | US | disclosed |
| US-7576221-B2 | N-(3-aminopropyl)-N-[(1R)-1-(1-benzyl-4-phenyl-1H-imidazol-2-yl)-2-methylpropyl]-4-methylbenzamide; kinesin-related proteins (KRP) inhibitors; anticarcinogenic agent | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2009-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227680-A1 | Amino Acid Derivatives | OPRL1, OPRK1, AVPR1A | LMNA 3623/4885SMN1; SMN2 1720/4885HTT 1869/4885 |
| US-20130178456-A1 | ARYLETHYNYL DERIVATIVES | GRM5, GRM1, GRM3 | LMNA 4558/4885SMN1; SMN2 3190/4885HTT 1094/4885 |
| US-20140155602-A1 | Arlethynyl Derivatives | GRM5, GRIK5, GRM1 | LMNA 4483/4885SMN1; SMN2 3667/4885HTT 1237/4885 |
| US-20090258016-A1 | Substituted imidazole derivatives | ABCG2, CYP2C19, AADAC | LMNA 4285/4885SMN1; SMN2 3720/4885HTT 2442/4885 |
| US-20130274464-A1 | Arylethynyl Derivatives | GRM5, GRM1, GRM3 | LMNA 4558/4885SMN1; SMN2 3190/4885HTT 1094/4885 |
| US-20130017196-A1 | SUBSTITUTED IMIDAZOLE DERIVATIVES | ABCG2, CYP2C19, AADAC | LMNA 4285/4885SMN1; SMN2 3720/4885HTT 2442/4885 |
| US-20110251169-A1 | Arylethynyl derivatives | GRM5, GRM1, GRM3 | LMNA 4558/4885SMN1; SMN2 3190/4885HTT 1094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.